Evaluation Of A Mobile Messaging Service In Improving Adherence Of Anti-Seizure Medications

Not Applicable

• Conditions: Mental and Behavioural Disorders; Nervous System Diseases

• Registration Number: PACTR202204553167288
• Lead Sponsor: niversity of Oxford

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-20
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 1200

Inclusion Criteria

Children or adults with a diagnosis of epilepsy ascertained by a clinician at the epilepsy clinic
Taking anti-seizure medications at the time of the study
Living within an area defined as the Kilifi Health Demographic Surveillance System, or the Nairobi Urban Health and Demographic Surveillance System at the time of the study or attending the epilepsy clinic in Kilifi or a KAWE-led clinic in Nairobi
Able to give written informed consent or assent in addition to parental consent (if aged between 13 and 17 years old) to participate in the study either by themselves or in the presence of an independent witness

Exclusion Criteria

Have intellectual disability
Do not have access to basic mobile phones
Are currently enrolled in ongoing interventions aimed at improving their health care

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adherence to anti-seizure medications measured through self-reports scales (eg the Morisky Medication Adherence Scale (MMAS-8)), checking record logs for correct intake of drugs and refill rates- validated by optimal and detectable levels in blood.

Secondary Outcome Measures

Name	Time	Method
Changes in seizure frequency, from many seizures to fewer seizures assessed by trained clinicians at the epilepsy clinics, through routine clinical examination.;Changes in stigma scores and quality of life scores, from higher scores to less scores for stigma and from lower scores to higher scores for quality of life assessed with standardized and locally adapted scales (assessed with the Kilifi Epilepsy Stigma Scale and World Health Organization Quality of Life Scale (WHOQOL-BREF), respectively).;Pharmacovigilance for unwanted drug-related adverse events as reported by participants will be assessed and confirmed using Common Toxicity Criteria for Adverse Events (CTCAE).<br>